Tag Archives: trastuzumabqyyp

FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin

Print this page March 11, 2019 – Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.2 “This is an important… Read More »